COMPANY PROFILE // THE 014 REPORT
Pyxis Oncology, Inc.
PYXS (Nasdaq)
Assembled from 2 government sources in 2.0 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
No flag from the records checked. 26 of 26 lists and sources checked came back clear (panel below).
✓ SEC filings✗ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
Pyxis Oncology, Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in Boston, MA; listed as PYXS (Nasdaq).[source] It reported revenue of $13.9 million for the fiscal year ended 2025-12-31.[source] It has filed 62 documents with the SEC in the last 12 months; the latest is Form 8-K, filed 2026-11-19.[source] Its largest institutional holders on 13F filings are GordonMD Global Investments LP, Pfizer Inc, Laurion Capital Management LP (as of 2026-06-30).[source] Every list and source checked for this page came back clear (26 of 26), dated in the checks panel.[source]
- red0
- amber0
- info0
- GordonMD Global Investments LP$30.2M
- Pfizer Inc$19.5M
- Laurion Capital Management LP$14.8M
- VANGUARD CAPITAL MANAGEMENT LLC$6.2M
- Atle Fund Management AB$2.9M
- BlackRock, Inc.$2.6M
- Palo Alto Investors LP$2.6M
- MARSHALL WACE, LLP$2.5M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Civik Thomas · Interim CEO (Director,Officer) · latest Form 4 2026-02-05 · filing · LinkedIn search
- Connealy Pamela Ann · CFO & COO (Officer) · latest Form 4 2025-04-02 · filing · LinkedIn search
- Sullivan Lara · President ,CEO & CMO (Director,Officer) · latest Form 4 2025-04-02 · filing · LinkedIn search
- Wadhane Jitendra · Prin Fin & Acct Officer (Officer) · latest Form 4 2026-03-25 · filing · LinkedIn search
- Cline Darren S · Director · latest Form 4 2026-03-25 · filing · LinkedIn search
- Dupont Jakob · Director · latest Form 4 2026-03-25 · filing · LinkedIn search
- FLAVIN JOHN L · Director · latest Form 4 2026-03-25 · filing · LinkedIn search
- HUMPHREY RACHEL · Director · latest Form 4 2026-03-25 · filing · LinkedIn search
- Lewis-Hall Freda C · Director · latest Form 4 2026-03-25 · filing · LinkedIn search
- Metzger Michael A · Director · latest Form 4 2026-03-25 · filing · LinkedIn search
- Palani Santhosh · Director · latest Form 4 2026-03-25 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Sidley Austin LLP · Exhibit 5.1 legal opinion, S-3 filed 2026-08-20
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001782223 | source |
| EIN | 83-1160910 | source |
| Business address (SEC) | 321 HARRISON AVENUE, BOSTON, MA, 02118 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 129 days · Next 10-K due (period ended 2026-12-31; <br>Emerging growth company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 174 days · Next 10-Q due (period ended 2027-03-31; <br>Emerging growth company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
ADDRESS · ZIP CODE
Location context
At the same address (3)
- Monte Rosa Therapeutics, Inc. · SEC registrant
- NEW ENGLAND FOUNDATION FOR THE ARTS INC · IRS-registered organization
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Bolt Biotherapeutics, Inc. · Dupont Jakob
- Helus Pharma Inc. · Lewis-Hall Freda C
- PLIANT THERAPEUTICS, INC. · Cline Darren S
- Repare Therapeutics Inc. · Civik Thomas
- Syndax Pharmaceuticals Inc · Metzger Michael A
- Xenon Pharmaceuticals Inc. · Cline Darren S
SEC registrants at the same address
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-19 filing 8-K items 7.01,8.01 · SEC EDGAR
- 2026-11-13 filing 8-K items 5.03,5.07 · SEC EDGAR
- 2026-11-05 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-05 filing 8-K items 2.02 · SEC EDGAR
- 2026-10-21 filing Proxy statement · SEC EDGAR
- 2026-10-09 filing PRE 14A · SEC EDGAR
- 2026-10-01 filing 8-K items 1.01,8.01,9.01 · SEC EDGAR
- 2026-10-01 filing 424B5 · SEC EDGAR
- 2026-09-29 filing 424B5 · SEC EDGAR
- 2026-09-29 filing 424B5 · SEC EDGAR
- 2026-09-09 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-09-08 officer change 8-K items 5.02,7.01,9.01 · SEC EDGAR
- 2026-08-28 filing 424B2 · SEC EDGAR
- 2026-08-27 filing EFFECT · SEC EDGAR
- 2026-08-20 filing S-3 · SEC EDGAR
- 2026-08-13 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-13 filing 8-K items 2.02 · SEC EDGAR
- 2026-07-02 filing 8-K items 1.01,3.02,7.01 · SEC EDGAR
- 2026-06-30 filing 144 · SEC EDGAR
- 2026-06-15 filing 8-K items 5.07 · SEC EDGAR
- 2026-05-14 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-14 filing 8-K items 2.02 · SEC EDGAR
- 2026-04-30 filing ARS · SEC EDGAR
- 2026-04-30 filing DEFA14A · SEC EDGAR
- 2026-04-30 filing Proxy statement · SEC EDGAR
- 2026-04-30 officer change 8-K/A items 5.02 · SEC EDGAR
- 2026-03-23 filing S-8 · SEC EDGAR
- 2026-03-23 filing Annual report (10-K) · SEC EDGAR
- 2026-03-23 filing 8-K items 2.02,7.01 · SEC EDGAR
- 2026-02-06 filing 8-K items 9.01 · SEC EDGAR
170 earlier entries
- 2025-12-18 filing 8-K items 7.01,8.01
- 2025-12-09 filing EFFECT
- 2025-12-08 filing CORRESP
- 2025-11-26 filing S-3
- 2025-11-03 filing Quarterly report (10-Q)
- 2025-11-03 filing 8-K items 2.02
- 2025-08-14 filing Quarterly report (10-Q)
- 2025-08-14 filing 8-K items 2.02
- 2025-08-04 filing 8-K items 8.01
- 2025-07-03 officer change 8-K items 5.02
- 2025-06-18 filing 8-K items 5.07
- 2025-05-15 filing Quarterly report (10-Q)
- 2025-05-15 filing 8-K items 2.02,7.01
- 2025-04-29 filing DEFA14A
- 2025-04-29 filing Proxy statement
- 2025-04-21 filing 144
- 2025-04-17 filing 144
- 2025-04-14 filing 144
- 2025-04-02 filing SCHEDULE 13D/A
- 2025-04-02 insider First Form 3/4/5 on record for Civik Thomas (Interim CEO)
- 2025-04-02 insider First Form 3/4/5 on record for Connealy Pamela Ann (CFO & COO)
- 2025-04-02 insider First Form 3/4/5 on record for Sullivan Lara (President ,CEO & CMO)
- 2025-04-02 insider First Form 3/4/5 on record for Wadhane Jitendra (Prin Fin & Acct Officer)
- 2025-04-02 insider First Form 3/4/5 on record for Cline Darren S (Director)
- 2025-04-02 insider First Form 3/4/5 on record for Dupont Jakob (Director)
- 2025-04-02 insider First Form 3/4/5 on record for FLAVIN JOHN L (Director)
- 2025-04-02 insider First Form 3/4/5 on record for HUMPHREY RACHEL (Director)
- 2025-04-02 insider First Form 3/4/5 on record for Lewis-Hall Freda C (Director)
- 2025-04-02 insider First Form 3/4/5 on record for Metzger Michael A (Director)
- 2025-04-02 insider First Form 3/4/5 on record for Palani Santhosh (Director)
- 2025-03-24 filing 8-K items 7.01,9.01
- 2025-03-18 filing S-8
- 2025-03-18 filing Annual report (10-K)
- 2025-03-18 officer change 8-K items 2.02,5.02,7.01,9.01
- 2025-02-26 filing 8-K items 8.01
- 2025-02-04 filing 8-K items 8.01
- 2024-12-23 filing SCHEDULE 13D/A
- 2024-12-19 filing 8-K items 8.01,9.01
- 2024-11-20 filing 8-K items 7.01,9.01
- 2024-11-12 filing S-8
- 2024-11-12 filing Quarterly report (10-Q)
- 2024-11-12 filing 8-K items 2.02
- 2024-10-23 filing 8-K items 5.07,9.01
- 2024-09-25 filing Proxy statement
- 2024-09-13 filing PRE 14A
- 2024-08-14 filing Quarterly report (10-Q)
- 2024-08-14 filing 8-K items 2.02,9.01
- 2024-06-12 filing 8-K items 5.07
- 2024-06-10 officer change 8-K items 5.02,7.01,9.01
- 2024-05-14 filing Quarterly report (10-Q)
- 2024-05-14 filing 8-K items 2.02,9.01
- 2024-04-26 filing ARS
- 2024-04-26 filing DEFA14A
- 2024-04-26 filing Proxy statement
- 2024-04-04 filing 424B2
- 2024-04-03 filing EFFECT
- 2024-04-03 filing SC 13D/A
- 2024-04-01 filing CORRESP
- 2024-03-29 filing UPLOAD
- 2024-03-27 filing S-3
- 2024-03-27 filing 8-K items 8.01,9.01
- 2024-03-27 filing 8-K items 8.01,9.01
- 2024-03-22 filing S-8
- 2024-03-21 filing Annual report (10-K)
- 2024-03-21 filing 8-K items 2.02,7.01,9.01
- 2024-03-13 officer change 8-K items 5.02,7.01,9.01
- 2024-02-28 filing 8-K items 1.01,3.02,7.01,9.01
- 2023-11-28 officer change 8-K items 5.02,9.01
- 2023-11-07 filing Quarterly report (10-Q)
- 2023-11-07 filing 8-K items 2.02,9.01
- 2023-10-27 filing 8-K/A items 9.01
- 2023-09-18 filing 144
- 2023-09-14 filing 144
- 2023-09-13 filing 144
- 2023-09-12 filing 144
- 2023-09-11 filing 144
- 2023-09-06 filing UPLOAD
- 2023-09-05 filing 144
- 2023-08-28 filing CORRESP
- 2023-08-24 filing EFFECT
- 2023-08-23 filing S-8 POS
- 2023-08-23 filing POS AM
- 2023-08-23 filing S-8
- 2023-08-23 officer change 8-K items 2.01,5.02,7.01,9.01
- 2023-08-16 filing UPLOAD
- 2023-08-11 filing 144
- 2023-08-11 filing Quarterly report (10-Q)
- 2023-08-11 filing 425
- 2023-08-11 filing 8-K items 2.02,9.01
- 2023-08-11 filing 425
- 2023-08-11 filing 8-K items 8.01,9.01
- 2023-08-01 filing 144
- 2023-07-31 filing 144
- 2023-07-28 filing 144/A
- 2023-07-27 filing 144
- 2023-07-21 filing 144
- 2023-07-11 filing 144
- 2023-06-30 filing EFFECT
- 2023-06-30 filing 425
- 2023-06-30 officer change 8-K items 5.02
- 2023-06-30 filing 424B3
- 2023-06-29 filing CORRESP
- 2023-06-29 filing S-4/A
- 2023-06-16 filing 144
- 2023-06-15 filing UPLOAD
- 2023-06-13 filing 8-K items 5.07
- 2023-06-08 filing 144
- 2023-06-08 filing S-4
- 2023-06-07 filing 144
- 2023-05-30 filing 425
- 2023-05-25 filing 425
- 2023-05-24 filing 425
- 2023-05-24 filing 425
- 2023-05-24 filing 8-K items 7.01,9.01
- 2023-05-24 filing 425
- 2023-05-24 filing 425
- 2023-05-24 officer change 8-K items 1.01,5.02,7.01,8.01,9.01
- 2023-05-11 filing Quarterly report (10-Q)
- 2023-05-11 filing 8-K items 2.02,9.01
- 2023-05-10 filing 10-K/A
- 2023-04-28 filing ARS
- 2023-04-28 filing DEFA14A
- 2023-04-28 filing Proxy statement
- 2023-04-04 filing SC 13D/A
- 2023-03-28 officer change 8-K items 5.02
- 2023-03-22 filing S-8
- 2023-03-22 filing Annual report (10-K)
- 2023-03-22 officer change 8-K items 2.02,5.02
- 2023-03-16 filing 8-K items 7.01,9.01
- 2022-12-01 filing 8-K items 8.01,9.01
- 2022-11-14 filing EFFECT
- 2022-11-10 filing CORRESP
- 2022-11-03 filing UPLOAD
- 2022-11-01 filing S-3
- 2022-11-01 filing Quarterly report (10-Q)
- 2022-11-01 filing 8-K items 2.02,9.01
- 2022-10-07 filing 8-K items 1.01,3.02
- 2022-08-15 filing Quarterly report (10-Q)
- 2022-08-15 officer change 8-K items 2.02,5.02,9.01
- 2022-08-09 officer change 8-K items 5.02
- 2022-07-01 filing S-8
- 2022-06-14 filing 8-K items 5.07
- 2022-05-23 filing SC 13D/A
- 2022-05-13 filing Quarterly report (10-Q)
- 2022-05-13 filing 8-K items 2.02,9.01
- 2022-04-28 filing DEFA14A
- 2022-04-28 filing Proxy statement
- 2022-04-14 officer change 8-K items 5.02,8.01,9.01
- 2022-03-29 filing S-8
- 2022-03-29 filing Annual report (10-K)
- 2022-03-29 filing 8-K items 2.02,8.01,9.01
- 2021-11-15 filing Quarterly report (10-Q)
- 2021-11-15 filing 8-K items 2.02,9.01
- 2021-10-22 filing S-8
- 2021-10-22 filing SC 13D
- 2021-10-08 filing 424B4
- 2021-10-07 filing EFFECT
- 2021-10-07 filing S-1MEF
- 2021-10-07 filing SEC STAFF LETTER
- 2021-10-07 filing S-1/A
- 2021-10-06 filing CERT
- 2021-10-05 filing 8-A12B
- 2021-10-05 filing CORRESP
- 2021-10-05 filing CORRESP
- 2021-10-04 filing S-1/A
- 2021-10-01 filing S-1/A
- 2021-09-28 filing CORRESP
- 2021-09-17 filing Registration (S-1)
- 2021-09-17 filing SEC STAFF LETTER
- 2021-09-10 filing DRS/A
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-19 (within 7 days) 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event
- 2026-11-13 (within 30 days) 8-K filed: Item 5.03 charter or bylaw amendment; Item 5.07 shareholder vote
- 2026-11-05 (within 30 days) 10-Q filed
- 2026-11-05 (within 30 days) 8-K filed: Item 2.02 results of operations
- 2026-10-21 (older) DEF 14A filed
- 2026-10-09 (older) PRE 14A filed
- 2026-10-01 (older) 8-K filed: Item 1.01 material agreement; Item 8.01 other event; Item 9.01 exhibits
- 2026-10-01 (older) 424B5 filed (FORM 424B5)
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-22; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:PYXS The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
2 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1782223 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | PYXS / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 831160910 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001782223 | SEC EDGAR / IRS |
| CUSIP | 747324101 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001782223 | SEC EDGAR |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $13,858,000 | 2025-12-31 | 10-K, XBRL Revenues | as filed | 2026-11-22 09:12 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$79,621,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-22 09:12 UTC | Report an error |
| Total assets (at 2025-12-31) | $91,520,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-22 09:12 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $53,408,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-22 09:12 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $15,422,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-22 09:12 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 09:12 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 09:12 UTC | Report an error |
| State of incorporation | DE | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 09:12 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 09:12 UTC | Report an error |
| Business address | 321 HARRISON AVENUE, BOSTON, MA, 02118 | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 09:12 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 09:12 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$63,502,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-22 09:12 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $9,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-22 09:12 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $18,650,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-22 09:12 UTC | Report an error |
| Form D total offering amount (D filed 2021-03-22) | $172,499,998 | 2021-03-22 | D | as filed | 2026-11-22 09:12 UTC | Report an error |
| Form D total amount sold (D filed 2021-03-22) | $172,499,998 | 2021-03-22 | D | as filed | 2026-11-22 09:12 UTC | Report an error |
| Form D industry group | Other Health Care | 2021-03-22 | D | as filed | 2026-11-22 09:12 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2021-03-22 | D | as filed | 2026-11-22 09:12 UTC | Report an error |
| Form D date of first sale | 2021-03-05 | 2021-03-22 | D | as filed | 2026-11-22 09:12 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-05 · accession 0001193125-26-448612
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$19,984,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-05 | 0001193125-26-448612 | 2026-11-22 09:12 UTC | Report an error |
| Cash and cash equivalents | $3,856,000 | at 2026-09-30 | 10-Q | 2026-11-05 | 0001193125-26-448612 | 2026-11-22 09:12 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-19 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event
- 2026-11-13 Filing 8-K filed: Item 5.03 charter or bylaw amendment; Item 5.07 shareholder vote
- 2026-11-05 Filing 10-Q filed
- 2026-11-05 Filing 8-K filed: Item 2.02 results of operations
- 2026-10-21 Filing DEF 14A filed
- 2026-10-09 Filing PRE 14A filed
- 2026-10-01 Filing 8-K filed: Item 1.01 material agreement; Item 8.01 other event; Item 9.01 exhibits
- 2026-10-01 Filing 424B5 filed (FORM 424B5)
- 2026-09-29 Filing 424B5 filed (FORM 424B5)
- 2026-09-29 Filing 424B5 filed (FORM 424B5)
- 2026-09-09 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-09-08 Filing 8-K filed: Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-28 Filing 424B2 filed
- 2026-08-27 Filing EFFECT filed
- 2026-08-20 Filing S-3 filed
- 2026-08-13 Filing 10-Q filed
- 2026-08-13 Filing 8-K filed: Item 2.02 results of operations
- 2026-07-02 Filing 8-K filed: Item 1.01 material agreement; Item 3.02 unregistered equity sale; Item 7.01 Regulation FD disclosure
- 2026-06-15 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-05-14 Filing 10-Q filed
- 2026-05-14 Filing 8-K filed: Item 2.02 results of operations
- 2026-04-30 Filing ARS filed
- 2026-04-30 Filing DEFA14A filed
- 2026-04-30 Filing DEF 14A filed
- 2026-04-30 Filing 8-K/A filed: Item 5.02 officer or director change
8-K item text, as filed (excerpts)
- 2026-11-19 8-K Item 7.01, Regulation FD Disclosure
On November 18, 2026, Pyxis Oncology, Inc. (the “Company”) issued a press release announcing updated data from its ongoing global Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma. On November 19, 2026, the Company made available on its website a related corporate presentation for use that day in its Late-Breaking Oral Presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. A copy of the press release is attached as Exhibit 99.1 and the corporate presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K. The… the 8-K · retrieved 2026-11-22 09:12 UTC - 2026-11-19 8-K Item 8.01, Other Events
On November 18, 2026, the Company announced updated data from its ongoing global Phase 1 monotherapy study evaluating micvotabart pelidotin (MICVO) in patients with second-line and beyond (2L+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The cutoff date for all data reported below is October 14, 2026. Updated MICVO Phase 1 Monotherapy Trial Results as of October 14, 2026 Table 1: Survival and Durability Data Categories October 2026 Median progression-free survival (mPFS), months 6.7 12-month overall survival (OS) probability, % 81% Median duration of response (mDOR), months 9.2 Data as of 14-Oct-2026 Table 2: Response Data Categories Groups (N) October 2026… the 8-K · retrieved 2026-11-22 09:12 UTC - 2026-11-13 8-K Item 5.03, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
As discussed below under Item 5.07, on November 13, 2026 at Pyxis Oncology, Inc.’s (the “Company”) Special Meeting of Stockholders (the “Special Meeting”), the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to increase the number of authorized shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), from 190,000,000 shares to 380,000,000 shares (the “Authorized Share Increase”). On November 13, 2026, the Company filed a Certificate of Amendment to the Certificate of Incorporation (the “Charter Amendment”) with the Secretary of State of the State of Delaware to… the 8-K · retrieved 2026-11-22 09:12 UTC - 2026-11-13 8-K Item 5.07, Submission of Matters to a Vote of Security Holders
On November 13, 2026, the Company held the Special Meeting at 10:00 a.m. Eastern Standard Time in a virtual format via live audio webcast. As of October 8, 2026, the Company’s record date, there were a total of 119,583,637 shares of Common Stock outstanding and entitled to vote at the Special Meeting. At the beginning of the Special Meeting, 84,997,679 shares of Common Stock were present virtually, in person or by proxy, and, therefore, a quorum was present. Two items of business were acted upon by the stockholders at the Special Meeting. The final results for the votes regarding each proposal are set forth below. Proposal One: Approval of the Authorized Share Increase The stockholders… the 8-K · retrieved 2026-11-22 09:12 UTC - 2026-11-05 8-K Item 2.02, Results of Operations and Financial Condition
On November 5, 2026, Pyxis Oncology, Inc. (“the Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in Item 2.02 of this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the U.S. Securities and Exchange Commission made by… the 8-K · retrieved 2026-11-22 09:12 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | GordonMD Global Investments LP | $30,174,976 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:12 UTC | Report an error |
| 2 | Pfizer Inc | $19,480,773 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:12 UTC | Report an error |
| 3 | Laurion Capital Management LP | $14,751,673 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:12 UTC | Report an error |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | $6,248,751 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:12 UTC | Report an error |
| 5 | Atle Fund Management AB | $2,909,041 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:12 UTC | Report an error |
| 6 | BlackRock, Inc. | $2,612,481 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:12 UTC | Report an error |
| 7 | Palo Alto Investors LP | $2,601,474 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:12 UTC | Report an error |
| 8 | MARSHALL WACE, LLP | $2,499,936 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:12 UTC | Report an error |
| 9 | RENAISSANCE TECHNOLOGIES LLC | $2,324,418 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:12 UTC | Report an error |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | $1,782,698 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:12 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
2 state and city records carry this company's exact name, from 1 source. Possible matches only.
ClinicalTrials.gov (2)
possible match: matched by name only, not merged (2)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchPyxis Oncology · exact name match to 'Pyxis Oncology, Inc.' (no other entity shares the name) · sx:ctgov:h7056a1ea4ef5f6e6 Compare
- possible matchPyxis Oncology, Inc · exact legal name · sx:ctgov:h8dc97555c2989f01 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1782223.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001782223. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.